<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">epidemiology</journal-id><journal-title-group><journal-title xml:lang="ru">Эпидемиология и Вакцинопрофилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Epidemiology and Vaccinal Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-3046</issn><issn pub-type="epub">2619-0494</issn><publisher><publisher-name>«Numicom» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31631/2073-3046-2023-22-1-13-21</article-id><article-id custom-type="elpub" pub-id-type="custom">epidemiology-1746</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Особенности гуморального иммунного ответа к SARS-CoV-2 у медицинских работников временного инфекционного госпиталя</article-title><trans-title-group xml:lang="en"><trans-title>Features of the Formation of Seroprevalence to SARS-CoV2 in the Population of the Republic of Tatarstan during the Spread of COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3584-6861</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Решетникова</surname><given-names>И. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Reshetnikova</surname><given-names>I. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Решетникова Ирина Дмитриевна – кандидат медицинских наук, доцент, заместитель директора по научной работе, Казанский НИИ эпидемиологии и микробиологии Роспотребнадзора; доцент кафедры внутренних болезней ИФМиБ КФУ.</p><p>420015, Казань, ул. Б. Красная, 67; 420008; Казань, ул. Кремлевская. 18</p><p>Тел.: +7 (843) 236-67-21, факс +7 (843) 236-67-41, +7 (903) 305-18-16</p></bio><bio xml:lang="en"><p>Irina D. Reshetnikova – Cand. Sci. (Med.), Deputy Head of Kazan Scientific Research Institute of Epidemiology and Microbiology; Associate Professor at the Kazan Federal University.</p><p>67, Bolshaya Krasnaya str., Kazan, Russia, 420015; 18, Kremlevskaya, Kazan, Russia, 420008</p><p>Tel.: +7 (843) 236-67-21, fax: +7 (843) 236-67-41, +7 (903) 305-18-16</p></bio><email xlink:type="simple">reshira@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4411-8786</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Агафонова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Agafonova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Агафонова Елена Валентиновна – кандидат медицинских наук, врач клинической лабораторной диагностики консультативно-диагностической поликлиники инфекционно-аллергических заболеваний Казанский НИИЭМ Роспотребнадзора; ассистент кафедры пропедевтики детских болезней КГМУ.</p><p>Казань</p></bio><bio xml:lang="en"><p>Elena V. Agafonova – Cand. Sci. (Med.), laboratory diagnostics doctor of Kazan Scientific Research Institute of Epidemiology and Microbiology; assistant Department of Propedeutics of Childhood Diseases Kazan State Medical University of the Ministry of Health of Russia.</p><p>Kazan</p></bio><email xlink:type="simple">agafono@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7895-0012</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хакимов</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Khakimov</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хакимов Нияз Маратович – кандидат медицинских наук, доцент кафедры эпидемиологии и доказательной медицины.</p><p>Казань</p></bio><bio xml:lang="en"><p>Niyaz M. Khakimov – Cand. Sci. (Med.), Associate Professor at the Department of Epidemiology and Evidence-Based Medicine Kazan State Medical University of the Ministry of Health of Russia.</p><p>Kazan</p></bio><email xlink:type="simple">hakimniaz@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2536-3604</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тюрин</surname><given-names>Ю. A.</given-names></name><name name-style="western" xml:lang="en"><surname>Tyurin</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тюрин Юрий Александрович – кандидат медицинских наук, заведующий лабораторией иммунологии и разработки аллергенов, ведущий научный сотрудник, Казанский НИИЭМ Роспотребнадзора; доцент кафедры биохимии и клинической лабораторной диагностики КГМУ.</p><p>Казань</p></bio><bio xml:lang="en"><p>Yuriy A. Tyurin – Cand. Sci. (Med.), Head of immunology laboratory of Kazan Scientific Research Institute of Epidemiology and Microbiology; Associate Professor at the at the Department of Biochemistry and Clinical Laboratory Diagnostics Kazan State Medical University of the Ministry of Health of Russia.</p><p>Kazan</p></bio><email xlink:type="simple">tyurin.yurii@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шайхразиева</surname><given-names>Н. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Shaуkhrazieva</surname><given-names>N. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шайхразиева Наталья Дмитриевна – кандидат медицинских наук, доцент кафедры эпидемиологии и дезинфектологии.</p><p>Казань</p></bio><bio xml:lang="en"><p>Natalya D. Shaуkhrazieva – Cand. Sci. (Med.), Associate Professor at the Department of Epidemiology and Disinfectology of Kazan State Medical Academy of the Ministry of Health of Russia.</p><p>Kazan</p></bio><email xlink:type="simple">epid-gkb7@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8029-6515</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зиатдинов</surname><given-names>В. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Ziatdinov</surname><given-names>V. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зиатдинов Васил Билалович – доктор медицинских наук, директор Казанского НИИЭМ Роспотребнадзора.</p><p>Казань</p></bio><bio xml:lang="en"><p>Vasil B. Ziatdinov – Dr. Sci. (Med.), Head of Kazan Scientific Research Institute of Epidemiology and Microbiology.</p><p>Kazan</p></bio><email xlink:type="simple">kniem@mail.ru</email><xref ref-type="aff" rid="aff-5"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Казанский НИИ эпидемиологии и микробиологии Роспотребнадзора; ИФМиБ Казанского (Приволжского) федерального университета</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan Scientific Research Institute of Epidemiology and Microbiology; Kazan Federal University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Казанский НИИ эпидемиологии и микробиологии Роспотребнадзора; Казанский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan Scientific Research Institute of Epidemiology and Microbiology; Kazan State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Казанский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Казанская государственная медицинская академия – филиал РМАНПО Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Казанский НИИ эпидемиологии и микробиологии Роспотребнадзора; Казанская государственная медицинская академия – филиал РМАНПО Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kazan Scientific Research Institute of Epidemiology and Microbiology; Kazan Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>05</day><month>03</month><year>2023</year></pub-date><volume>22</volume><issue>1</issue><fpage>13</fpage><lpage>21</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Решетникова И.Д., Агафонова Е.В., Хакимов Н.М., Тюрин Ю.A., Шайхразиева Н.Д., Зиатдинов В.Б., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Решетникова И.Д., Агафонова Е.В., Хакимов Н.М., Тюрин Ю.A., Шайхразиева Н.Д., Зиатдинов В.Б.</copyright-holder><copyright-holder xml:lang="en">Reshetnikova I.D., Agafonova E.V., Khakimov N.M., Tyurin Y.A., Shaуkhrazieva N.D., Ziatdinov V.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epidemvac.ru/jour/article/view/1746">https://www.epidemvac.ru/jour/article/view/1746</self-uri><abstract><p>Актуальность. Изучение особенностей формирования и длительности сохранения гуморального иммунного ответа на новую коронавирусную инфекцию в группе высокого риска заражения – у медицинских работников (МР) – является актуальным направлением исследований. Цель. Изучить динамику выработки специфических антител (IgM и IgG) к SARS-CoV2 у невакцинированных МР временного инфекционного госпиталя для оценки трендов индивидуального гуморального иммунного ответа на новую коронавирусную инфекцию. Материалы и методы. Проводили мониторинг выработки IgM и IgG к SARS-CoV-2 в сыворотке крови 68 невакцинированных МР ежемесячно с июля 2020 г. по июль 2021 г. методом двухстадийного прямого твердофазного ИФА. Среди наблюдаемых было 26,5% мужчин и 73,5% женщин, средний возраст составил 43,5 ± 1,51 лет, 52,9% врачей, 36,8% среднего медицинского персонала и 10,3% младшего персонала. У 69,1% участвовавших в исследовании отмечались в анамнезе клинические проявления COVID-19, среди них 42,7% перенесли инфекцию в лёгкой форме, 20,6% – в среднетяжёлой и 5,9% – в тяжёлой форме, 30,9% – бессимптомно. Результаты и обсуждение. Показано снижение среднегеометрического значения титров IgM к SARS-CoV-2 (среднемесячное снижение - 6,40%) и увеличение среднегеометрического значения титров IgG (среднемесячное увеличение 4,26%) в обследуемой когорте. Индивидуальная оценка динамики антител от дня с впервые полученным положительным результатом показала снижение среднегеометрических значений титров антител и IgM и IgG к SARS-CoV-2 (среднемесячное уменьшение -23,56% и -1,18% соответственно). Индивидуальная оценка иммунного ответа позволила выделить три группы по динамике выявления IgM: М0 – IgM в крови отсутствовали (50 ± 5,7446%); М1 – IgM сохранялись в течение 1–2 месяцев с последующим быстрым снижением титра (16,176 ± 3,7943%); М2 – IgM сохранялись в крови на протяжении трёх и более месяцев (33,824 ± 5,1033%). По характеру динамики IgG МР были разделены на четыре труппы. G0 – медленный тренд снижения титра IgG, нет превышения 95% верхней доверительной границы индивидуального тренда ни в одной из взятых проб (19,2 ± 4,7%); G1 – быстрый тренд снижения титра IgG, нет превышения 95% верхней доверительной границы индивидуального тренда начиная с 3-го месяца после начала наблюдения (4,4 ± 2,5%); G2 – неравномерный тренд снижения IgG, есть превышения 95% верхней доверительной границы индивидуального тренда, начиная с 3-го месяца после начала наблюдения (69,1 ± 5,6%); G3 –тренд увеличения титра иммуноглобулинов IgG (7,353 ± 3,1651%). Выводы. Результаты серологического мониторинга свидетельствуют о формировании коллективного иммунитета в данной когорте. Наблюдение за напряжённостью индивидуального иммунного ответа к SARS-CoV-2 на протяжении года демонстрирует естественное течение инфекционного процесса и является основанием для проведения вакцинации против COVID-19. Результаты серологического мониторинга могут быть использованы для прогнозирования эпидемиологической ситуации, планирования мероприятий специфической и неспецифической профилактики COVID-19, персонализации вакцинации.</p></abstract><trans-abstract xml:lang="en"><p>Relevance. It is relevant to study the features of the formation and duration of the humoral immune response to a new coronavirus infection in a high-risk group of infection - among medical workers. Aims. To study the dynamics of the levels of specific antibodies (IgM and IgG) to SARS-CoV2 in unvaccinated MRs of the temporary infectious diseases hospital to assess the trends of the individual humoral immune response to a new coronavirus infection. Materials and methods. We monitored IgM and IgG to SARS-CoV-2 in 68 unvaccinated healthcare workers monthly from July 2020 to July 2021 by two-stage direct solid-phase ELISA using the test systems «SARS-CoV-2-IgG-ELISA-BEST» and «SARS-CoV-2-IgM-ELISA-BEST», Russia. Among them, there were 26.5% men and 73.5% women, the average age was 43.5 ± 1.51 years, doctors 52.9%, paramedical personnel 36.8% and junior staff 10.3%. 69.1% had a history of clinical manifestations of COVID19, among them 42.7% had a mild infection, 20.6% had a moderate infection, and 5.9% had a severe infection, 30.9% were asymptomatic. Statistical processing were carried out using the methods of variation statistics using the Excel statistical package and the WinPepi software product (version 11.65). Results. A decrease in the geometric mean value of IgM titers to SARS-CoV-2 (average monthly decrease of 6.40%) and an increase in the geometric mean value of IgG titers (average monthly increase of 4.26%). An individual assessment of the dynamics of antibodies from the day with the first positive result showed a decrease in the geometric mean values of antibody titers and IgM and IgG to SARS-CoV-2 (monthly average decrease of -23.56% and -1.18%, respectively). An individual assessment of the immune response made it possible to distinguish three groups according to the dynamics of IgM: M0 -IgM in the blood were absent (50 ± 5.7446%); M1 -IgM persisted for        1–2 months, followed by a rapid decrease in titer (16.176 ± 3.7943%); M2 – IgM remained in the blood for three or more months (33.824 ± 5.1033%). By the nature of the dynamics of IgG MR were divided into four troupes. With a downward trend in IgG titer: G0 – IgG does not exceed 95% of the upper confidence limit of the individual trend in any of the samples taken (19.118 ± 4.7686%), G1 – does not exceed 95% of the upper confidence limit of the individual trend starting from 3 months after the start observations (4.412 ± 2.4903%), G2 – there is an excess of 95% of the upper confidence limit of the individual trend starting from 3 months after the start of observation (69.118 ± 5.6027%); G3 – with a trend of increasing IgG titer (7.353 ± 3.1651%). Сonclusions. The results of serological monitoring as a whole indicate the formation of herd immunity in this cohort. Monitoring the intensity of the individual immune response to SARS-CoV-2 throughout the year reflects the natural course of the infectious process and is the basis     for vaccination against COVID-19. The results of serological monitoring can be used to predict the epidemiological situation, plan specific and non-specific COVID-19, personalization of vaccination.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>серологический мониторинг SARS-CoV-2</kwd><kwd>медицинские работники</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>serological monitoring of SARS-CoV-2</kwd><kwd>healthcare workers</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена частично за счет средств субсидии, выделенной в рамках государственной поддержки Казанского (Приволжского) федерального университета в целях повышения его конкурентоспособности среди ведущих мировых научно-образовательных центров.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Fei Xiang, Xiaorong Wang, Xinliang He, et al. Antibody detection and dynamic characteristics in Patients with COVID-19. Clin Infect Dis. 2020 Apr 19: ciaa461. doi: 10.1093/cid/ciaa461.</mixed-citation><mixed-citation xml:lang="en">Fei Xiang, Xiaorong Wang, Xinliang He, et al. Antibody detection and dynamic characteristics in Patients with COVID-19. Clin Infect Dis. 2020 Apr 19: ciaa461. doi: 10.1093/cid/ciaa461</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Juanjuan Zhao, Quan Yuan, Haiyan Wang, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 [published online ahead of print, 2020 Mar 28]. Clin Infect Dis. 2020, ciaa344. https://doi.org/10.1093/cid/ciaa3443.</mixed-citation><mixed-citation xml:lang="en">Juanjuan Zhao, Quan Yuan, Haiyan Wang, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 [published online ahead of print, 2020 Mar 28]. Clin Infect Dis. 2020, ciaa344. https://doi.org/10.1093/cid/ciaa344</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Попова А. Ю., Ежлова Е. Б., Мельникова А. А. и др. Популяционный иммунитет к SARS-CoV-2 среди населения Санкт-Петербурга в период эпидемии COVID-19. Проблемы особо опасных инфекций. 2020;(3):124–130. https://doi.org/10.21055/0370-1069-2020-3-124-130</mixed-citation><mixed-citation xml:lang="en">Popova A.Yu., Ezhlova E.B., Melnikova A.A., et al. Population immunity to SARS-CoV-2 among the population of St. Petersburg during the COVID-19 epidemic. Problems of especially dangerous infections. 2020;(3):124–130 (In Russ). https://doi.org/10.21055/0370-1069-2020-3-124-130</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Попова А. Ю., Ежлова Е. Б., Мельникова А. А. и др. Оценкa популяционного иммунитета к SARS-CoV-2 среди населения Ленинградской области в период эпидемии COVID-19. Проблемы особо опасных инфекций. 2020;(3):114–123. https://doi.org/10.21055/0370-1069-2020-3-114-123</mixed-citation><mixed-citation xml:lang="en">Popova A.Yu., Ezhlova E.B., Melnikova A.A., et al. Assessment of population immunity to SARS-CoV-2 among the population of the Leningrad region during the COVID-19 epidemic. Problems of especially dangerous infections. 2020;(3):114–123 (In Russ). https://doi.org/10.21055/0370-1069-2020-3-114-123</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Попова А. Ю., Ежлова Е. Б., Мельникова А. А. и др. Характеристика популяционного иммунитета к SARS-CoV-2 у жителей Саратова и Саратовской области в период эпидемии COVID-19. Проблемы особо опасных инфекций. 2020;(4):106–116. https://doi.org/10.21055/0370-1069-2020-4-106-116</mixed-citation><mixed-citation xml:lang="en">Popova A.Yu., Ezhlova E.B., Melnikova A.A., et al. Characteristics of population immunity to SARS-CoV-2 in residents of Saratov and the Saratov region during the COVID-19 epidemic. Problems of especially dangerous infections. 2020;(4):106–116 (In Russ). https://doi.org/10.21055/0370-1069-2020-4-106-116</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Попова А. Ю., Ежлова Е. Б., Мельникова А. А. и др. Распределение серопревалентности к SARS-CoV-2 среди жителей Тюменской области в эпидемическом периоде COVID-19. Журнал микробиологии, эпидемиологии и иммунобиологии 97 (5), 2020, 392–400 https://doi.org/10.36233/0372-9311-2020-97-5-1</mixed-citation><mixed-citation xml:lang="en">Popova A.Yu., Ezhlova E.B., Melnikova A.A., et al. Distribution of seroprevalence to SARS-CoV-2 among residents of the Tyumen region in the epidemic period of COVID-19. Journal of Microbiology, Epidemiology and Immunobiology 97(5), 2020, 392–400 (In Russ). https://doi.org/10.36233/0372-9311-2020-97-5-1</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Попова А. Ю., Ежлова Е. Б., Мельникова А. А. и др. Уровень серопревалентности к SARS-CoV-2 среди жителей Хабаровского края на фоне эпидемии COVID-19. Журнал микробиологии, эпидемиологии и иммунобиологии 2021; 98(1)7017https://doi.org/10.36233/0372-9311-92</mixed-citation><mixed-citation xml:lang="en">Popova A. Yu., Ezhlova E. B., Melnikova A. A., et al. The level of seroprevalence to SARS-CoV-2 among residents of the Khabarovsk Territory against the backdrop of the COVID-19 epidemic. Journal of Microbiology, Epidemiology and Immunobiology 2021; 98(1)7017 (In Russ). https://doi.org/10.36233/0372-9311-92</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Попова А. Ю., Ежлова Е. Б., Мельникова А. А. и др. Характеристика серопревалентности к SARS-СoV-2 среди населения Республики Татарстан на фоне COVID-19. Журнал микробиологии, эпидемиологии и иммунобиологии. 2020; 97(6):518–528. DOI: https://doi.org/10.36233/0372-9311-2020-97-6-2).</mixed-citation><mixed-citation xml:lang="en">Popova A.Yu., Ezhlova E.B., Melnikova A.A., et al. Characterization of seroprevalence to SARS-СoV-2 among the population of the Republic of Tatarstan against the background of COVID-19. Journal of Microbiology, Epidemiology and Immunobiology. 2020; 97(6):518–528 (In Russ). DOI: https://doi.org/10.36233/0372-9311-2020-97-6-2</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X, Lam JY, Wong WM, et al. Accurate diagnosis of COVID-19 by a novel immunogenic secreted SARS-CoV-2 orf8 protein. MBio. 2020;11(5):e02431–20. doi:10.1128/mBio.02431-20</mixed-citation><mixed-citation xml:lang="en">Wang X, Lam JY, Wong WM, et al. Accurate diagnosis of COVID-19 by a novel immunogenic secreted SARS-CoV-2 orf8 protein. MBio. 2020;11(5):e02431–20. doi:10.1128/mBio.02431-20</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Федоров В. С., Иванова О. Н., Карпенко И. Л. и др. Иммунный ответ на новую коронавирусную инфекцию. Клиническая практика. 2021;12(1):33–40. doi: 10.17816/clinpract64677</mixed-citation><mixed-citation xml:lang="en">Fedorov V.S., Ivanova O.N., Karpenko I.L., et al. Immune response to a new coronavirus infection. Clinical practice. 2021;12(1):33–40 (In Russ). doi:10.17816/clinpract64677</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Secchi M, Bazzigaluppi E, Brigatti C, et al. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. J Clin Invest. 2020;130(12):6366–6378. doi: 10.1172/JCI142804</mixed-citation><mixed-citation xml:lang="en">Secchi M, Bazzigaluppi E, Brigatti C, et al. COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. J Clin Invest. 2020;130(12):6366–6378. doi: 10.1172/JCI142804</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wu LP, Wang NC, Chang YH, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562–1564. doi: 10.3201/eid1310.070576</mixed-citation><mixed-citation xml:lang="en">Wu LP, Wang NC, Chang YH, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562–1564. doi: 10.3201/eid1310.070576</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Choe PG, Perera R, Park WB, et al. MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015. Emerg Infect Dis. 2017;23(7):1079–1084. doi: 10.3201/eid2307.170310,</mixed-citation><mixed-citation xml:lang="en">Choe PG, Perera R, Park WB, et al. MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015. Emerg Infect Dis. 2017;23(7):1079–1084. doi: 10.3201/eid2307.170310</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cao WC, Liu W, Zhang PH, et al. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357(11):1162–1163. doi: 10.1056/NEJMc070348.</mixed-citation><mixed-citation xml:lang="en">Cao WC, Liu W, Zhang PH, et al. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357(11):1162–1163. doi: 10.1056/NEJMc070348.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Qiu M, Shi Y, Guo Z, et al. Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect. 2005;7(5–6):882–889. doi: 10.1016/j.micinf.2005.02.006</mixed-citation><mixed-citation xml:lang="en">Qiu M, Shi Y, Guo Z, et al. Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect. 2005;7(5-6):882–889. doi: 10.1016/j.micinf.2005.02.006</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gluck V, Grobecker S, Tydykov L, et al. SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19. Infection. 2021;1–8. doi:10.1007/s15010-021-01598-6</mixed-citation><mixed-citation xml:lang="en">Gluck V, Grobecker S, Tydykov L, et al. SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19. Infection. 2021;1–8. doi:10.1007/s15010-021-01598-6</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lumley SF, Wei J, O,Donnell D, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin Infect Dis. 2021;ciab004. doi: 10.1093/cid/ciab004]</mixed-citation><mixed-citation xml:lang="en">Lumley SF, Wei J, O, Donnell D, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin Infect Dis. 2021;ciab004. doi: 10.1093/cid/ciab004]</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gerco den Hartog G, Vos ER, van den Hoogen LL, et al. Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study. Clin Infect Dis. 2021;ciab172. doi: 10.1093/cid/ciab172</mixed-citation><mixed-citation xml:lang="en">Gerco den Hartog G, Vos ER, van den Hoogen LL, et al. Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study. Clin Infect Dis. 2021;ciab172. doi: 10.1093/cid/ciab172</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Figueiredo-Campos P, Blankenhaus B, Mota C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur J Immunol. 2020;50(12):2025–2040. doi: 10.1002/eji.202048970</mixed-citation><mixed-citation xml:lang="en">Figueiredo-Campos P, Blankenhaus B, Mota C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur J Immunol. 2020;50(12):2025–2040. doi: 10.1002/eji.202048970</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Li J, Li H, et al. Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients. Int Immunopharmacol.2021;90:107271. doi: 10.1016/j.intimp.2020.107271</mixed-citation><mixed-citation xml:lang="en">Wang Y, Li J, Li H, et al. Persistence of SARS-CoV-2-specific antibodies in COVID-19 patients. Int Immunopharmacol.2021;90:107271. doi: 10.1016/j.intimp.2020.107271</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kumar N, Bhartiya S, Singh T. Duration of anti-SARS-CoV-2 antibodies much shorter in India. Vaccine. 2021; 39(6):886–888. https://doi.org/10.1016/j.vaccine.2020.10.094</mixed-citation><mixed-citation xml:lang="en">Kumar N, Bhartiya S, Singh T. Duration of anti-SARS-CoV-2 antibodies much shorter in India. Vaccine. 2021; 39(6):886–888. https://doi.org/10.1016/j.vaccine.2020.10.094</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Алешкин А. В., Новикова Л. И., Бочкарева С. С. и др. Динамика антител к различным антигенам коронавируса SARS-CoV-2 у больных с подтверждённой инфекцией COVID-19. Бюллетень экспериментальной биологии и медицины. 2021.Т.171,№2.С.230–233. DOI: 10.47056/0365-9615-2021-171-2-196-199</mixed-citation><mixed-citation xml:lang="en">Aleshkin AV, Novikova LI, Bochkareva SS, et al. Dynamics of antibodies to various antigens of the SARS-CoV-2 coronavirus in patients with confirmed COVID-19 infection. 2021;171(2):230–233 (In Russ). DOI: 10.47056/0365-9615-2021-171-2-196-199</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">F Javier Ibarrondo, Jennifer A Fulcher, David Goodman-Meza, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.Engl J Med . 2020 Sep 10;383(11):1085–1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.</mixed-citation><mixed-citation xml:lang="en">Wajnberg A, Amanat F, Firpo A, et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. July 17, 2020 (https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1. opens in new tab).</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Wajnberg A, Amanat F, Firpo A, et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. July 17, 2020 (https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1. opens in new tab).</mixed-citation><mixed-citation xml:lang="en">F Javier Ibarrondo, Jennifer A Fulcher, David Goodman-Meza, et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19.Engl J Med . 2020 Sep 10;383(11):1085–1087. doi: 10.1056/NEJMc2025179. Epub 2020 Jul 21.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Bölke E, Matuschek Ch, Fischer JC. Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. N Engl J Med. 2020 Oct 22; 383(17):1694–1695. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23. DOI: 10.1056/NEJMc2027051</mixed-citation><mixed-citation xml:lang="en">Wajnberg A, Amanat F, Firpo A, et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. July 17, 2020 (https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1. opens in new tab).</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Палтышев И. П. и др. Основы описательной эпидемиологии: учеб.-метод. пособие для аспирантов, обучающихся по специальности 14.02.02. Эпидемиология. Казань. МеДДоК. 2019:110.</mixed-citation><mixed-citation xml:lang="en">Bölke E, Matuschek Ch, Fischer JC. Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. N Engl J Med. 2020 Oct 22; 383(17):1694–1695. doi: 10.1056/NEJMc2027051. Epub 2020 Sep 23. DOI: 10.1056/NEJMc2027051</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Садыков М. Н., Зиатдинов В. Б., Решетникова И. Д. и др. Изучение уровня и структуры популяционного иммунитета к SARS-CoV2 у населения Республики Татарстан в период второго пика распространения COVID-19. Эпидемиология и Вакцинопрофилактика. 2021;20(5):39–51.</mixed-citation><mixed-citation xml:lang="en">Paltyshev I.P. et al. Fundamentals of descriptive epidemiology: study method. manual for graduate students studying in the specialty 14.02.02. Epidemiology. Kazan. MED-Doc. 2019:110 (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Решетникова И. Д., Тюрин Ю. А., Агафонова Е. В. и др. Изучение особенностей гуморального иммунного ответа к новой коронавирусной инфекции COVID-19 среди медицинских работников. Инфекция и иммунитет. 2021;11(5):934–942. https://doi.org/10.15789/2220-7619-SOT-1587</mixed-citation><mixed-citation xml:lang="en">Sadykov M.N., Ziatdinov V.B., Reshetnikova I.D., et al. Study of the level and structure of population immunity to SARS-CoV2 in the population of the Republic of Tatarstan during the second peak of the spread of COVID-30. Epidemiology and Vaccinal Prevention. 2021;20(5):39–30 (In Russ). https://doi.org/10.31631/2073-3046-2021-20-5-39–51</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Супрун Е. Н. Динамика иммунного ответа. Аллергология и иммунология в педиатрии. 2014. №2 (37). Доступно на: https://cyberleninka.ru/article/n/dinamika-immunnogo-otveta (дата обращения: 14.09.2022).</mixed-citation><mixed-citation xml:lang="en">Reshetnikova I.D., Tyurin Yu.A., Agafonova E.V., et al. Studying the characteristics of the humoral immune response to the new coronavirus infection COVID-19 among medical workers. Infection and immunity. 2021;11(5):934–942. (In Russ). https://doi.org/10.15789/2220-7619-SOT-1587</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Suprun E.N. Dynamics of the immune response. Allergology and immunology in pediatrics. 2014. No. 2 (37) (In Russ). Available at: https://cyberleninka.ru/article/n/dinamika-immunnogo-answer (date of access: 09/14/2022).</mixed-citation><mixed-citation xml:lang="en">Suprun E.N. Dynamics of the immune response. Allergology and immunology in pediatrics. 2014. No. 2 (37) (In Russ). Available at: https://cyberleninka.ru/article/n/dinamika-immunnogo-answer (date of access: 09/14/2022).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
